MetaCap

AIM ImmunoTech (AIM) vs Scilex (SCLX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AIM ImmunoTech is the larger company by market cap ($4.6 million vs $4.0 million), about 1.1 times the size, while Scilex is growing revenue faster (-46.5% vs -48.2%). Scilex converts more of its revenue into profit, with a net margin of -1236.4% versus -15861.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AIM-37.31%SCLX-83.79%
+4%-42%-88%
Oct 7, 20261 yearNov 20, 2026
AIM-36.33%SCLX-80.62%
+4%-40%-85%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AIM versus SCLX key metrics
MetricAIMSCLX
Share price$0.1146$0.5658
Market cap$4.57M$3.98M
1-day change-4.50%-12.95%
YTD return—-92.55%
1-year return—-95.96%
5-year return—-99.74%
Forward P/E—0.78
EPS (TTM)$-1.20$-49.70
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$88.00K$30.25M
Revenue growth (YoY)-48.24%-46.54%
Net income (latest FY)$-13.96M$-374.05M
Gross margin—415.83%
Operating margin-13254.55%-1143.71%
Net margin-15861.36%-1236.42%
52-week high$1.82$14.34
52-week low$0.1068$0.50
Distance from 52-week high-93.72%-96.05%
Analyst consensusnone—
Avg. price target upside+3608.55%—
Average volume4.40M56.11K
Shares outstanding39.92M7.03M
Employees1934
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Scilex is more profitable, keeping -1236.4 cents of every revenue dollar as net income versus -15861.4 cents for AIM ImmunoTech.

About AIM ImmunoTech

AIM stock →

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees

About Scilex

SCLX stock →

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees

AIM vs SCLX FAQ

Which is bigger, AIM ImmunoTech or Scilex?

AIM ImmunoTech (AIM) is larger, with a market capitalization of $4.57M compared with $3.98M for Scilex (SCLX).

Are AIM ImmunoTech and Scilex in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons